Navigation Links
US FDA approves ABILIFY for adolescent patients with schizophrenia
Date:11/6/2007

TOKYO, JAPAN and PRINCETON, NJ, Nov. 6, 2007 -- Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for the atypical antipsychotic ABILIFY(R) (aripiprazole) for the treatment of schizophrenia in adolescents aged 13-17 years. In adolescents, ABILIFY treats positive and negative symptoms of schizophrenia. The FDA first approved ABILIFY for the treatment of schizophrenia in adults on November 15, 2002.

"Until now, FDA-approved treatment options for adolescent patients with schizophrenia were limited," said Robert Findling, M.D., Director of Child and Adolescent Psychiatry, University Hospitals Case Medical Center, Cleveland, Ohio. "The approval of this new indication for ABILIFY provides an additional effective treatment option for these patients."

This approval is based on results from a six-week, randomized, double-blind, placebo-controlled study that demonstrated significant improvement with ABILIFY compared to placebo on the primary efficacy endpoint, Positive and Negative Syndrome Scale (PANSS) Total Score. (1)

"We are extremely pleased that ABILIFY, the first available dopamine partial agonist, is approved for the treatment of pediatric patients (13 to 17 years of age) suffering from schizophrenia," said Tatsuo Higuchi, President and Representative Director, Otsuka Pharmaceutical Co., Ltd. "ABILIFY offers an effective new option to help treat this serious mental illness."

"Schizophrenia is one of the most complex of all mental health disorders," said Elliott Sigal, M.D., Ph.D., Executive Vice President, Chief Scientific Officer and President, Research and Development, Bristol-Myers Squibb. "We remain committed to providing innovative therapies, such as ABILIFY, to help patients, including adolescents, living with schizophrenia."

Clinical Trial Design and Findings


'/>"/>
Contact: Debra Kaufmann
debra.kaufmann@otsuka.com
240-683-3568
Otsuka America Pharmaceutical, Inc.
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. FDA Approves New Roche West Nile Virus Blood Screening Test
3. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
4. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
5. FDA Approves SOMA(R) (carisoprodol) 250 mg
6. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
7. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. ABIH Approves Certification Credit for SSPC Training Courses
10. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
11. FDA Approves New Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Ticket Down is a reputable source for authentic Paul ... South Carolina. Fans of Paul McCartney have to be ... originally kicked off in 2013. The most visited continent of ... performer recently announced that he would be adding additional dates ... in Charlottesville, VA at John Paul Jones Arena on ...
(Date:5/4/2015)... 2015 CCL, a top-ranked, global provider ... program to other leadership development consultancies. “The CCL ... and successful practitioners, expanding our capacity to drive results ... John R. Ryan, CCL President and CEO. , As ... Partner Network , it will schedule a one-on-one conference ...
(Date:5/4/2015)... May 04, 2015 San Diego ... ceremony at their brand new, 13,700 square foot facility ... new building will not only provide fertility treatment and ... also offer community and educational events to a number ... is located next door to their current Carmel Valley/Del ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Dr. Benjamin ... Georgia proudly offers the latest non-surgical double-chin eliminator. ... facial plastic surgeon in Atlanta to offer Kybella ... to be injected specifically under the chin, promising to ... , Before Kybella, patients who sought immediate solutions for ...
(Date:5/4/2015)... 04, 2015 Unlike some camps, the Nike Middle ... The goal is to educate first and train second, with ... ensures that the young runners are building the knowledge base needed ... of the topics covered include Effort Based Training, Running Heroes, Running ... to be? This is not a camp where kids come ...
Breaking Medicine News(10 mins):Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 3Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2
... Abramson, MD, professor of medicine and director of ... hosted a webinar with colleagues from the medical ... together, bench, bedside and the blogosphere to discuss ... RA. The webinar can be viewed at: , ...
... FRIDAY, June 10 (HealthDay News) -- Women are more likely ... a new study contends. A nuclear stress test, also ... blood flow to the heart muscle at rest and during ... heart disease, but it,s expensive and exposes people to radiation. ...
... -- Preschool children with symptoms of attention-deficit/hyperactivity disorder (ADHD) ... an important role in cognitive and motor control, new ... develop ways to treat the common behavioral disorder in ... Kennedy Krieger Institute in Baltimore. In the study, ...
... HealthDay Reporter , THURSDAY, June 9 (HealthDay News) -- The ... new support from a study in mice -- and the ... control weight gain. It,s always a leap to extrapolate ... does open up interesting possibilities. "Humans have basically the ...
... Respirology issues a serious warning of massive ... Dr Ken Takahashi, Acting Director of the WHO Collaborating ... important data on asbestos use in 47 Asian countries ... the highest age-adjusted mortality rates in Asia. This study ...
... - Negative family attitudes can have an adverse effect ... study. Researchers found that although family members, ... mentally ill, they can also be the source of ... recovery. "Negative attitudes of family members have the ...
Cached Medicine News:Health News:NYU Langone rheumatologists share insight with online RA community 2Health News:Women May Be Getting Unneeded Heart Imaging Tests 2Health News:Brain Scan Spots Differences in Tots With ADHD Symptoms 2Health News:Mouse Study Reveals How Smoking Helps Keep People Thin 2Health News:Deaths and major morbidity from asbestos-related diseases in Asia likely to surge in next 20 years 2Health News:Mothers Play Important Role in Recovery From Mental Illness 2
(Date:5/4/2015)... Calif. , May 4, 2015  Impax Laboratories, ... filled two key executive leadership roles, appointing  Donna M. ... Deborah M. Penza , as Senior Vice President, Chief ... report to Impax,s President and Chief Executive Officer, ... Donna and Deborah have joined the Impax team," said ...
(Date:5/4/2015)... -- Bayer HealthCare (Bayer) has entered into an exclusive ... ) on ISIS-FXI Rx, an antisense investigational drug ... the agreement Bayer will further develop and commercialize ISIS-FXI ... As part of the clinical development program, Bayer plans ... in an appropriate patient community. "Bayer is ...
(Date:5/4/2015)... ANGELES , May 4, 2015  CytRx ... and development company specializing in oncology, today announced ... 1b aldoxorubicin combination studies pairing aldoxorubicin with either ... of gemcitabine or ifosfamide with escalating doses of ... and even at the lowest dose level of ...
Breaking Medicine Technology:Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 3Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7
... ZymoGenetics,Inc. today announced that interim findings were presented ... B-cell chronic,lymphocytic leukemia (B-CLL) at the American Society ... included intravenous,administration of higher doses than had been ... was well-tolerated and biologically,active at all dose levels ...
... Biotechnology,Inc. (OTCBB: CGRB) today announced that positive interim ... prostate cancer drug candidate,CB7630 (abiraterone acetate) was presented ... Meeting, which is currently,taking place in Chicago, Illinois. ... Saturday, June 2nd, as part of the poster,discussion ...
Cached Medicine Technology:ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 2ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 5Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ASCO Annual Meeting 6